White Paper: Anatomy of a failure to launch: A review of barriers to generic and biosimilar market entry and the use of competition law as a remedy

(more…)

COVID-19 “Round 2” – Findings & way forward (Kearney)

Why is Now the Right Time to Modernise the Eu Variations System?

AMR Industry Alliance 2020 Progress Report

Perceptions and recommendations of physicians/KOLs on value added medicines

Open

Overarching recommendations for improved access to generic and biosimilar medicines in the hospital setting

Improving healthcare delivery in hospitals by optimized utilization of medicines

A digital future for value added medicines

Calls to action to improve access to value added medicines

Case Studies for Value Added Medicines. Unlocking the potential of patient-centric continuous innovation

Medicines For Europe